BR112016007112A2 - Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação - Google Patents

Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação

Info

Publication number
BR112016007112A2
BR112016007112A2 BR112016007112A BR112016007112A BR112016007112A2 BR 112016007112 A2 BR112016007112 A2 BR 112016007112A2 BR 112016007112 A BR112016007112 A BR 112016007112A BR 112016007112 A BR112016007112 A BR 112016007112A BR 112016007112 A2 BR112016007112 A2 BR 112016007112A2
Authority
BR
Brazil
Prior art keywords
ang
human angiopoietin
binds human
antibody
combination
Prior art date
Application number
BR112016007112A
Other languages
English (en)
Inventor
Klein Christian
Thomas Markus
Mueller Philipp
Zippelius Alfred
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016007112A2 publication Critical patent/BR112016007112A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS QUE SE LIGAM A ANGIOPOIETINA 2 (ANG-2) HUMANA, USOS DE UM ANTICORPO QUE SE LIGA A ANGIOPOIETINA 2 (ANG-2) HUMANA E COMBINAÇÃO. A presente invenção refere-se à terapia de combinação de um anticorpo que se liga a angiopoietina 2 (ANG-2) humana com um agonista de CD40.
BR112016007112A 2013-12-20 2014-12-17 Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação BR112016007112A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198753 2013-12-20
EP14158331 2014-03-07
PCT/EP2014/078233 WO2015091655A1 (en) 2013-12-20 2014-12-17 Combination therapy with an anti-ang2 antibody and a cd40 agonist

Publications (1)

Publication Number Publication Date
BR112016007112A2 true BR112016007112A2 (pt) 2017-09-19

Family

ID=52278610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007112A BR112016007112A2 (pt) 2013-12-20 2014-12-17 Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação

Country Status (20)

Country Link
US (3) US20150232548A1 (pt)
EP (1) EP3082857B1 (pt)
JP (1) JP6345787B2 (pt)
KR (1) KR20160085888A (pt)
CN (1) CN105611944A (pt)
AU (1) AU2014368695A1 (pt)
BR (1) BR112016007112A2 (pt)
CA (1) CA2923591A1 (pt)
CL (1) CL2016001586A1 (pt)
CR (1) CR20160199A (pt)
EA (1) EA201600474A1 (pt)
HK (1) HK1221409A1 (pt)
IL (1) IL244454A0 (pt)
MX (1) MX2016008099A (pt)
PE (1) PE20160753A1 (pt)
PH (1) PH12016500482A1 (pt)
SG (1) SG11201604594SA (pt)
TW (1) TWI559931B (pt)
WO (1) WO2015091655A1 (pt)
ZA (1) ZA201601895B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106573981A (zh) 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
CA2963606A1 (en) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
BR112017009817A2 (pt) 2014-11-10 2018-02-14 Hoffmann La Roche anticorpos anti-il-1beta e métodos de utilização
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
EA035268B1 (ru) 2015-06-29 2020-05-22 Бристол-Маерс Сквибб Компани Антитела к cd40
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
MX2020005463A (es) * 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN112168960A (zh) * 2019-07-03 2021-01-05 义慧科技(深圳)有限公司 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Also Published As

Publication number Publication date
CR20160199A (es) 2016-06-17
TW201526915A (zh) 2015-07-16
IL244454A0 (en) 2016-04-21
PH12016500482A1 (en) 2016-05-16
JP6345787B2 (ja) 2018-06-20
MX2016008099A (es) 2016-10-13
SG11201604594SA (en) 2016-07-28
EP3082857B1 (en) 2018-07-25
ZA201601895B (en) 2018-11-28
JP2017504600A (ja) 2017-02-09
PE20160753A1 (es) 2016-08-01
HK1221409A1 (zh) 2017-06-02
US20200199215A1 (en) 2020-06-25
EA201600474A1 (ru) 2016-11-30
KR20160085888A (ko) 2016-07-18
US20180134780A1 (en) 2018-05-17
EP3082857A1 (en) 2016-10-26
WO2015091655A1 (en) 2015-06-25
TWI559931B (en) 2016-12-01
CN105611944A (zh) 2016-05-25
AU2014368695A1 (en) 2016-04-14
US20150232548A1 (en) 2015-08-20
CA2923591A1 (en) 2015-06-25
CL2016001586A1 (es) 2017-05-12

Similar Documents

Publication Publication Date Title
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
BR112016000903A2 (pt) anticorpos
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
BR112016030670A2 (pt) "imunocitoquina"
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112016022841A2 (pt) cadeia j modificada
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
BR112017001031A2 (pt) apresentação assistida de janelas de aplicativo
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016001782A2 (pt) Proteína de fusão terapêutica
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112015023557A2 (pt) proteínas de ligações dual específicas direcionadas contra tnfa
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112016014731A2 (pt) Anticorpos anti-baff

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]